David Turkaly
Stock Analyst at JMP Securities
(2.40)
# 1,416
Out of 4,667 analysts
137
Total ratings
43.27%
Success rate
-2.21%
Average return
Main Sectors:
Stocks Rated by David Turkaly
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Market Outperform | $265 | $213.88 | +23.90% | 16 | Nov 18, 2024 | |
| NVRO Nevro | Reiterates: Market Perform | n/a | $4.37 | - | 14 | Nov 12, 2024 | |
| LNTH Lantheus Holdings | Maintains: Market Outperform | $125 → $112 | $87.15 | +28.51% | 7 | Nov 7, 2024 | |
| ENOV Enovis | Initiates: Market Outperform | $62 | $46.04 | +34.67% | 1 | Oct 3, 2024 | |
| APYX Apyx Medical | Reiterates: Market Perform | n/a | $1.38 | - | 5 | Sep 16, 2024 | |
| KIDS OrthoPediatrics | Reiterates: Market Outperform | $50 | $26.29 | +90.19% | 9 | Sep 13, 2024 | |
| STIM Neuronetics | Maintains: Market Outperform | $7 → $3 | $0.81 | +272.67% | 7 | Aug 14, 2024 | |
| HAE Haemonetics | Reiterates: Market Outperform | $125 | $85.66 | +45.93% | 10 | Aug 13, 2024 | |
| TELA TELA Bio | Maintains: Market Outperform | $15 → $12 | $2.86 | +319.58% | 5 | Aug 13, 2024 | |
| AXGN Axogen | Maintains: Market Outperform | $17 → $20 | $13.12 | +52.50% | 6 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $40 → $35 | $22.92 | +52.71% | 13 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $23 → $20 | $10.48 | +90.93% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $32 | $12.20 | +162.30% | 6 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $18.61 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $285 | $190.60 | +49.53% | 14 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $160 → $140 | $108.80 | +28.68% | 13 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $84.61 | - | 1 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $4 | $1.54 | +159.74% | 4 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $7.90 | -36.71% | 1 | Oct 6, 2017 |
STERIS
Nov 18, 2024
Reiterates: Market Outperform
Price Target: $265
Current: $213.88
Upside: +23.90%
Nevro
Nov 12, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $4.37
Upside: -
Lantheus Holdings
Nov 7, 2024
Maintains: Market Outperform
Price Target: $125 → $112
Current: $87.15
Upside: +28.51%
Enovis
Oct 3, 2024
Initiates: Market Outperform
Price Target: $62
Current: $46.04
Upside: +34.67%
Apyx Medical
Sep 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $1.38
Upside: -
OrthoPediatrics
Sep 13, 2024
Reiterates: Market Outperform
Price Target: $50
Current: $26.29
Upside: +90.19%
Neuronetics
Aug 14, 2024
Maintains: Market Outperform
Price Target: $7 → $3
Current: $0.81
Upside: +272.67%
Haemonetics
Aug 13, 2024
Reiterates: Market Outperform
Price Target: $125
Current: $85.66
Upside: +45.93%
TELA Bio
Aug 13, 2024
Maintains: Market Outperform
Price Target: $15 → $12
Current: $2.86
Upside: +319.58%
Axogen
Aug 9, 2024
Maintains: Market Outperform
Price Target: $17 → $20
Current: $13.12
Upside: +52.50%
Jul 30, 2024
Maintains: Market Outperform
Price Target: $40 → $35
Current: $22.92
Upside: +52.71%
May 9, 2024
Maintains: Market Outperform
Price Target: $23 → $20
Current: $10.48
Upside: +90.93%
May 7, 2024
Reiterates: Market Outperform
Price Target: $32
Current: $12.20
Upside: +162.30%
Apr 22, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $18.61
Upside: -
Feb 23, 2024
Reiterates: Market Outperform
Price Target: $285
Current: $190.60
Upside: +49.53%
Nov 13, 2023
Maintains: Market Outperform
Price Target: $160 → $140
Current: $108.80
Upside: +28.68%
May 24, 2023
Reiterates: Market Perform
Price Target: n/a
Current: $84.61
Upside: -
Apr 13, 2023
Maintains: Outperform
Price Target: $7 → $4
Current: $1.54
Upside: +159.74%
Oct 6, 2017
Initiates: Outperform
Price Target: $5
Current: $7.90
Upside: -36.71%